Clinical and Translational Research Accelerator, Yale School of Medicine, New Haven, CT 06520, USA. Electronic address: https://twitter.com/ruey_hu.
Department of Internal Medicine, Yale New Haven Hospital, P.O. Box 208030, New Haven, CT, 06520-8030, USA. Electronic address: https://twitter.com/aschwann212.
Cardiol Clin. 2023 Nov;41(4):511-524. doi: 10.1016/j.ccl.2023.06.007.
The conventional sequence of guideline-directed medical therapy (GDMT) initiation in heart failure with reduced ejection fraction (HFrEF) assumes that the effectiveness and tolerability of GDMT agents mirror their order of discovery, which is not true. In this review, the authors discuss flexible GDMT sequencing that should be permitted in special populations, such as patients with bradycardia, chronic kidney disease, or atrial fibrillation. Moreover, the initiation of certain GDMT medications may enable tolerance of other GDMT medications. Most importantly, the achievement of partial doses of all four pillars of GDMT is better than achievement of target dosing of only a couple.
在射血分数降低的心力衰竭(HFrEF)中,常规的指南指导的药物治疗(GDMT)起始顺序假定 GDMT 药物的有效性和耐受性与其发现顺序相对应,但事实并非如此。在这篇综述中,作者讨论了在特殊人群中应允许的灵活 GDMT 排序,例如心动过缓、慢性肾脏病或心房颤动患者。此外,某些 GDMT 药物的起始使用可能使其他 GDMT 药物的耐受性得以实现。最重要的是,实现 GDMT 的所有四个支柱的部分剂量要好于仅实现几个支柱的目标剂量。